Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 5;11:575. doi: 10.3389/fphar.2020.00575

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Xu, Guo, Du, Liu, Wang and Chen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The activity evaluation of Britanin on breast cancer model mouse in vivo. (A) Representative bioluminescence images in an untreated control group of MDA-MB-231 luc inoculated mice tumor model. (B) Quantification of bioluminescence intensity by ROIs that encompass the tumor. Data represent as the means ± S.D. (C) Representative bioluminescence images recorded before and after injection Britanin of 5 mg/kg every 2 d for 27 d by intraperitoneal injection in MDA-MB-231 luc inoculated mice tumor models as the test group. (D) Quantification of the tumor bioluminescence ROIs. Data represent as the means ± S.D. (E) The mouse was weighed before and after Britanin injections, and there was no significant difference with an untreated control group. (F) Tumor volume was calculated before and after Britanin injections. (G) Photograph of excised tumors from the control, test treatment group. The graph represents the average volume of the tumor. ***P < 0.001.